Tocilizumab in severe COVID-19: A promise fulfilled.
作者信息
Levi Marcel
机构信息
Amsterdam University Medical Center, Department of Vascular Medicine, , Amsterdam, the Netherlands; University College London Hospitals NHS Foundation Trust, Department of Medicine, UK; Cardiometabolic Programme-NIHR UCLH/UCL BRC, London, UK.
出版信息
Eur J Intern Med. 2022 Jan;95:38-39. doi: 10.1016/j.ejim.2021.11.015. Epub 2021 Nov 22.
Abstract
摘要
相似文献
1
Tocilizumab in severe COVID-19: A promise fulfilled.托珠单抗治疗重症新型冠状病毒肺炎：承诺兑现。
Eur J Intern Med. 2022 Jan;95:38-39. doi: 10.1016/j.ejim.2021.11.015. Epub 2021 Nov 22.
2
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
3
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
4
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?托珠单抗降低重症 COVID-19 患者死亡率：我们应如何对其进行分级？
Br J Clin Pharmacol. 2022 Jul;88(7):3539-3541. doi: 10.1111/bcp.15283. Epub 2022 Mar 2.
5
Tocilizumab is recommended for the treatment of severe COVID-19.托珠单抗被推荐用于治疗重症新型冠状病毒肺炎。
EBioMedicine. 2020 Nov;61:103045. doi: 10.1016/j.ebiom.2020.103045. Epub 2020 Oct 7.
6
Tocilizumab for treatment of SARS-CoV-2 infection at home: A case report.托珠单抗治疗居家治疗的 SARS-CoV-2 感染：病例报告。
Acute Med. 2022;21(1):53-55. doi: 10.52964/AMJA.0894.
7
Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.托珠单抗用于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者：皮下注射与静脉输注对比
J Med Virol. 2021 Jan;93(1):69-70. doi: 10.1002/jmv.26124. Epub 2020 Jun 19.
8
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.托珠单抗使用时机对住院的2019冠状病毒病感染患者的影响
Respir Care. 2022 May;67(5):629-630. doi: 10.4187/respcare.10067.
9
Timing of Tocilizumab Use and COVID-19.托珠单抗的使用时机与新型冠状病毒肺炎
Respir Care. 2022 Mar;67(3):381-382. doi: 10.4187/respcare.09678.
10
Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease.托珠单抗与皮质类固醇联合治疗重症SARS-CoV-2疾病
Med Intensiva (Engl Ed). 2022 May;46(5):285-287. doi: 10.1016/j.medine.2022.02.013. Epub 2022 Feb 24.
引用本文的文献
1
Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets.重症新型冠状病毒肺炎侵袭性肺曲霉病的细胞因子谱及潜在治疗靶点
Diagnostics (Basel). 2022 Jun 1;12(6):1364. doi: 10.3390/diagnostics12061364.
2
Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure.托珠单抗治疗后血栓炎症生物标志物的变化趋势比严重SARS-CoV2相关呼吸衰竭患者的评分更能预测治疗失败。
Eur J Intern Med. 2022 Sep;103:111-112. doi: 10.1016/j.ejim.2022.06.004. Epub 2022 Jun 6.
3
Anticoagulation as secondary prevention of massive lung thromboses in hospitalized patients with COVID-19.抗凝治疗作为新冠病毒肺炎住院患者大面积肺血栓形成的二级预防措施
Eur J Intern Med. 2022 Jun;100:21-24. doi: 10.1016/j.ejim.2022.04.009. Epub 2022 Apr 13.
4
Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?血小板-白细胞相互作用与 COVID-19：血栓事件和炎症状态之间的相互联系如何影响治疗策略和疾病预后？
Thromb Res. 2022 May;213:179-194. doi: 10.1016/j.thromres.2022.03.022. Epub 2022 Mar 31.
Zotero 插件